Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia

BACKGROUND: In preclinical studies the heat shock protein 90 (Hsp90) inhibitor tanespimycin induced down-regulation of checkpoint kinase 1 (Chk1) and other client proteins as well as increased sensitivity of acute leukemia cells to cytarabine. We report here the results of a phase I and pharmacologi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kaufmann, Scott H., Karp, Judith E., Litzow, Mark R., Mesa, Ruben A., Hogan, William, Steensma, David P., Flatten, Karen S., Loegering, David A., Schneider, Paula A., Peterson, Kevin L., Maurer, Matthew J., Smith, B. Douglas, Greer, Jacqueline, Chen, Yuhong, Reid, Joel M., Ivy, S. Percy, Ames, Matthew M., Adjei, Alex A., Erlichman, Charles, Karnitz, Larry M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ferrata Storti Foundation 2011
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3208679/
https://ncbi.nlm.nih.gov/pubmed/21791475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.049551
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak